We've covered the potential value of systemic therapy for early stage NSCLC in a wide range of posts and podcasts, and to summarize what we've learned...
It's not uncommon for a question here to be about the a pathologist's terminology on a report that equivocates about whether a lesion is...
Following the terrific presentations by Drs. Ben Solomon and Ross Camidge on the science and clinical experience with the novel ALK inhibitor XALKORI...
The National Lung Screening Trial (NLST), a protocol with over 50,000 former or current smokers between ages 55 and 75, justifiably became a major...
Almost two months ago, I wrote about stage IV NSCLC in the elderly. There, I reviewed existing data and focused on the published results of the French...
Here is the second part of Dr. Socinski's summary from our ASCO Highlights in Lung Cancer program, covering an important presentation by Dr.
The first of several podcasts we'll be adding here from our ASCO 2012 Lung Cancer Highlights program, co-sponsored with LUNGevity Foundation, is with Dr. Mark Socinski, Professor at the University of Pittsburgh, who discussed the updated results of continuation maintenance therapy with Alimta (pemetrexed) on the PARAMOUNT trial.
The lung surgeons I work with are competitive, and the patients they treat are better for it. They monitor how many lymph nodes they are able collect from the mediastinoscopies and lung cancer surgeries they do, competing against their own targets and each other. Why?
I was disappointed to learn today that the FORTIS-M trial, a study of 720 patients with previously treated advanced NSCLC randomized to receive talactoferrin-alpha (TLF) or placebo, was reported as being negative in a press release late yesterday.
The response of cancers with a specific driver mutation , such as an EGFR mutation or ALK rearrangement, to a targeted inhibitor of that target, is often dramatic and long-lasting, but it is also almost always limited in duration, typically lasting several months or a few years. Beyond that point, we tend to see a subset of the cancer cells become resistant progress, perhaps manifested as one or several new lesions or growth of one area against a background of most of the remainder of the cancer still being well-controlled.
One of the questions that comes up fairly frequently is what to make of a "mixed response" to systemic therapy: after several weeks or months of treatment, a scan shows some areas of known disease shrinking, but others are growing. Why might this happen? What does it mean? And what should it lead us to do?
Folks here know that just about every day we discuss questions of what molecular marker test to order for lung cancer, how important it is, how it's done, what tissue is needed, and other very timely and practical issues in lung cancer. These are questions that evolve every few months, as new research emerges with different markers.
Here's the question and answer session that followed the presentations by Drs.
Last year, the PARAMOUNT trial was one of the highlight presentations in lung cancer from ASCO 2011, an important landmark study of continuation maintenance therapy with Alimta (pemetrexed).
Historically, lung cancer patients with a KRAS mutation, which is the molecular marker that is actually most common in patients with NSCLC (about 20-25%), have not had extremely appealing treatment options. In fact, the available data has largely led to the conclusion that both chemotherapy and EGFR inhibitor therapy tends to be, if anything, somewhat less effective for people with a KRAS mutation. Despite some reason for hope in early research with a few novel therapies, there really hasn't been a good alternative that is specifically effective for KRAS mutation-positive patien
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.